Defining treatment‐resistant depression
Background Varying conceptualizations of treatment‐resistant depression (TRD) have made
translating research findings or systematic reviews into clinical practice guidelines …
translating research findings or systematic reviews into clinical practice guidelines …
Ketamine and depression: a narrative review
A Corriger, G Pickering - Drug design, development and therapy, 2019 - Taylor & Francis
Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …
be reduced within several weeks after the start of conventional antidepressants, but …
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Z Walsh, OM Mollaahmetoglu, J Rootman, S Golsof… - BJPsych …, 2022 - cambridge.org
Background In the past two decades, subanaesthetic doses of ketamine have been
demonstrated to have rapid and sustained antidepressant effects, and accumulating …
demonstrated to have rapid and sustained antidepressant effects, and accumulating …
Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications
MP Dandekar, AJ Fenoy, AF Carvalho, JC Soares… - Molecular …, 2018 - nature.com
Although deep brain stimulation (DBS) is an established treatment choice for Parkinson's
disease (PD), essential tremor and movement disorders, its effectiveness for the …
disease (PD), essential tremor and movement disorders, its effectiveness for the …
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies
TH Pham, AM Gardier - Pharmacology & therapeutics, 2019 - Elsevier
Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
Ketamine in neuropsychiatric disorders: an update
The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …
development of neuropsychiatric therapeutics, one characterized by an antidepressant …
Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis
BackgroundDepression is considered to have the highest disability burden of all conditions.
Although treatment-resistant depression (TRD) is a key contributor to that burden, there is …
Although treatment-resistant depression (TRD) is a key contributor to that burden, there is …
An update on ketamine and its two enantiomers as rapid-acting antidepressants
K Zhang, K Hashimoto - Expert review of neurotherapeutics, 2019 - Taylor & Francis
Introduction: Depression is one of the most disabling diseases worldwide. Approximately
one-third of depressed patients are treatment-resistant to the currently available …
one-third of depressed patients are treatment-resistant to the currently available …
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
MS Salahudeen, CM Wright… - … advances in drug …, 2020 - journals.sagepub.com
This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …
The potential of predictive analytics to provide clinical decision support in depression treatment planning
RC Kessler - Current opinion in psychiatry, 2018 - journals.lww.com
Recommendations include using large prospective observational studies followed by
pragmatic trials rather than smaller, expensive controlled treatment trials for preliminary …
pragmatic trials rather than smaller, expensive controlled treatment trials for preliminary …